Image source: Getty Images
Bausch Health Companies (TSX:BHC) has seen some interesting momentum lately in the TSX. Its shares are now rising due to improving financials and strategic moves in its business. As the company works to reduce debt and grow its product portfolio, especially in eye health, now could be a good time to enter. Especially while the stock is still trading at a reasonable valuation. With great growth potential, Bausch could be the hidden gem investors are looking for. So today, let's take a look.
About Bausch
Bausch is a well-known player in the healthcare space, especially focused on eye health, gastrointestinal diseases and dermatology. Your flagship brand, Bausch + Lombis a global leader in eye care, offering everything from contact lenses to eye surgeries. Bausch has made waves with its innovation in pharmaceuticals and devices, continually expanding its product portfolio. Although the company has faced challenges with debt, it has been working diligently to pay it off. And this has sparked more confidence among investors.
Now could be an interesting time to keep an eye on Bausch (pun intended). With the stock showing positive momentum on the TSX and the company taking steps towards financial recovery, it's a promising opportunity for those looking to invest in a healthcare giant that still has room to grow, especially after recent earnings .
About profits
Bausch's most recent earnings report showed solid performance, with revenue of around $2.2 billion, a slight increase compared to previous quarters. Its eye care segment, powered by Bausch + Lomb, continued to perform strongly with notable growth in sales of contact lenses and prescription pharmaceuticals. While earnings per share (EPS) were slightly below expectations, the company made strides in reducing its debt. These investors have been watching closely. The focus on streamlining operations and increasing profitability has begun to show positive results.
When the earnings were announced, the market reaction was a bit mixed. On the one hand, revenue growth and progress in debt reduction were seen as positive, leading to a slight increase in the share price. On the other hand, the disappointing EPS raised some doubts. Overall, investors seemed cautiously optimistic, recognizing Bausch's long-term potential but remaining on the lookout for stronger profit margins ahead.
Looking forward
Currently, Bausch presents an intriguing opportunity for investors, especially those focused on value. With a forward price-to-earnings (P/E) ratio of just 2, the stock trades at a very low multiple compared to its peers. This suggests that the market may be underestimating Bausch's ability to generate future earnings, which could set the stage for higher returns. The company has also made progress in reducing its debt and increasing its operational efficiency, which could boost profitability in the future.
Market reactions have been cautiously optimistic as investors recognize the potential for significant upside. Bausch is firmly focused on core areas such as eye health and strong earnings before interest, taxes, depreciation and amortization (EBITDA) of $3 billion. Bausch is therefore better positioned to manage its significant debt load. If the company continues to execute its turnaround strategy, there is plenty of room for further stock appreciation, especially considering its low valuation metrics. For investors looking for a bargain in the healthcare sector, Bausch could be an attractive option with the potential for further gains in the future.